EXITING ACOR WITH PROFIT RIGHT HERE AT $32.61.
Our negative thesis on Acordia Therapeutics (ACOR) has not changed. However we are positive on the group, therefore we will exit the entire position right here and plan to short again on spikes up. For readers’ convenience an earlier partial post is copied below: Our thesis has not changed in